Menu
Close
Stories & News
Resources
Stay Informed
x
Stay Informed
September 15, 2021
Pfizer’s most recent quarterly dividend was its 331st in a row.1 The streak stretches back more than 80 years, spanning major innovation milestones and advances in healthcare.
In the past decade, Pfizer has paired strong financial results with bold scientific breakthroughs, including the Pfizer-BioNTech COVID-19 vaccine, marketed as Comirnaty, and blockbuster medicines and vaccines such as Ibrance and Prevnar.
The company has steadily increased the quarterly dividend, most recently with a 6 percent rise from 2019 to 2020, and currently yields more than 3%. In 2020 alone, Pfizer returned approximately $8.4 billion in cash dividends to shareholders.2
[1] Pfizer Declares Third-Quarter 2021 Dividend. Available here.
[2] Proxy Statement for 2021 Annual Meeting of Shareholders. Available here.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.